EUCTR2014-005059-25-Outside-EU/EEA进行中（未招募）不适用
A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents with Either MenACWY Conjugate Vaccine or Menomune®
ovartis Vaccines &Diagnostics, Inc.0 个研究点目标入组 210 人开始时间: 2014年11月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent of the subject was obtained and documented or, in the case of unemancipated minors, written informed consent of the parent or guardian with written informed assent of the subject.
- •2. Individuals in good health as determined by
- •- medical history
- •- physical assessment
- •- clinical judgment of the investigator
- •3. Subjects between the ages of 16 and 23 years inclusive
- •4. For subjects in groups I and II only, receipt of either MenACWY or Menomune®.
- •5. A negative urine pregnancy test was required for female subjects
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Individuals' parents or legal guardians or individuals who were unable to comprehend or unwilling to follow all required study procedures for the whole period of the study.
- •2. History of documented invasive meningococcal disease.
- •3. Received any other meningococcal vaccine at any time outside of study V59P6.
- •4. Receipt of any vaccines in the 14 days preceding Visit 4 (Day 1) or expected receipt through the final blood draw at Visit 6 (Day 29).
- •5. Received antibiotic therapy within the 72 hours prior to collection of a blood sample.
- •6. Actively enrolled or scheduled to be enrolled in another clinical study during the planned period of this trial.
- •7. Serious, chronic, or acute illnesses or diseases (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system).
- •8. Individuals with suspected HIV infection or HIV related disease, or history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or receipt of immunosuppressive therapy within 6 months.
- •9. Use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days.
- •10. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •11. Individuals who had any malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative disorder.
- •12. Acute medical illness with or without fever within 72 hours or an oral temperature=100.4°F (=38.0°C) at the time of inclusion.
- •13. Allergy to latex or items containing latex.
- •14. Administration of immune globulin or other blood products within the past 90 days.
- •15. Personal or family history of Guillain-Barré Syndrome.
- •16. Suspected or known hypersensitivity to any of the vaccine components.
- •17. Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
- •18. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- •19. Individuals who were part of study personnel or close family members conducting this study.
- •20. Any condition which, in the opinion of the investigator, posed a health risk to the participant or rendered them inappropriate for a research study.
研究者
相似试验
已完成
2 期
Everolimus as Monotherapy Treatment In First Line Metastatic Recurrent and/or Unresectable Renal Cell CarcinomaCTRI/2010/091/000609ovartis India Ltd
进行中（未招募）
1 期
A study of PRA023 in patients with Crohn's DiseaseCrohn's DiseaseEUCTR2021-000092-37-BEPrometheus Biosciences, Inc.50
进行中（未招募）
1 期
A study of PRA023 in patients with Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2021-000092-37-CZPrometheus Biosciences, Inc. a subsidiary of Merck & Co., Inc.50
进行中（未招募）
1 期
A study of PRA023 in patients with Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2021-000092-37-PLPrometheus Biosciences, Inc. a subsidiary of Merck & Co., Inc.50
进行中（未招募）
不适用
A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1)Influenza Vaccine in Non-elderly Adult and Elderly Subjects - NDActive immunoprofilaxis against potential pandemic influenza strain.MedDRA version: 9.1Level: LLTClassification code 10059429Term: Influenza immunisationEUCTR2007-000165-38-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.